PMN.US ProMIS Neurosciences Inc.

Healthcare Biotechnology USA Stocks
3.29 USD
Close of Nov 17, 2026
2.78 27.40
Market cap
USD 29.6M
P/E
-
P/B
0.60x
ROE
-89.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is PMN.US undervalued?

Graham number

The Graham number of ProMIS Neurosciences Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

ProMIS Neurosciences Inc. fundamental analysis

No fundamental analysis for ProMIS Neurosciences Inc. yet.

ProMIS Neurosciences Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About ProMIS Neurosciences Inc.

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS, which enables drug discovery through a combination of protein biology, physics, and supercomputing. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer's disease; PMN267 for the tr…

Full company profile